- Trials with a EudraCT protocol (149)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (27)
149 result(s) found for: Biliary tract.
Displaying page 1 of 8.
| EudraCT Number: 2014-002798-12 | Sponsor Protocol Number: 14.07 | Start Date*: 2014-09-24 | ||||||||||||||||
| Sponsor Name:Odense University Hospital | ||||||||||||||||||
| Full Title: Neoadjuvant chemotherapy in patients with biliary tract carcinomas - A Nordic phase II study | ||||||||||||||||||
| Medical condition: Patients with resectable intra- or extrahepatic biliary tract carcinomas. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-012398-36 | Sponsor Protocol Number: a003c | Start Date*: 2009-06-18 | |||||||||||||||||||||
| Sponsor Name:Helsinki University Hospital | |||||||||||||||||||||||
| Full Title: Patient-controlled sedation with propofol in ERCP:alfentanyl vs remifentanyl | |||||||||||||||||||||||
| Medical condition: Billiar tract and pancreatic disoderes | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2008-004762-83 | Sponsor Protocol Number: BILISCOPIN | Start Date*: 2008-10-15 | ||||||||||||||||||||||||||
| Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | ||||||||||||||||||||||||||||
| Full Title: Evaluation of the diagnostic efficacy of the CT cholangiography performed by administering an intra-venous contrast medium with biliary excretion (Biliscopin) in patients with malignancies of the b... | ||||||||||||||||||||||||||||
| Medical condition: Patients with obstructive jaundice due to a biliary malignancy (Klatskin tumor, tumor of the middle or distal bile ducts or Galbladder tumors) Patients with post-cholecistectomy iatrogenic lesions ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: IT (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2013-001812-30 | Sponsor Protocol Number: CFTSp048 | Start Date*: 2013-10-23 | |||||||||||
| Sponsor Name:The Christie NHS Foundation Trust | |||||||||||||
| Full Title: A Phase III, randomised, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy for patients with locally advanced/metastatic biliary tract c... | |||||||||||||
| Medical condition: Biliary tract cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002002-70 | Sponsor Protocol Number: BIT-2 | Start Date*: 2011-07-30 | |||||||||||
| Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
| Full Title: A RANDOMISED PHASE II TRIAL OF SECOND LINE THERAPY IN ADVANCED BILIARY TRACT CANCER: CAPECITABINE OR CAPECITABINE PLUS MITOMYCIN C (BIT-2) | |||||||||||||
| Medical condition: Locally advanced or metastatic adenocarcinoma of the biliary tract (intra or extra-hepatic biliary ducts, gallbladder, Ampulla of Vater). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002467-34 | Sponsor Protocol Number: AIO-YMO/HEP-0315 | Start Date*: 2017-07-19 | |||||||||||||||||||||||||||||||
| Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||||||||||||
| Full Title: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial | |||||||||||||||||||||||||||||||||
| Medical condition: Locally advanced or metastatic, non resectable, adenocarcinoma of the biliary tract including intrahepatic and extrahepatic bile duct | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-007968-42 | Sponsor Protocol Number: a001c | Start Date*: 2009-02-13 | |||||||||||||||||||||||||||||||
| Sponsor Name:Helsinki University Central Hospital | |||||||||||||||||||||||||||||||||
| Full Title: Patient-controlled sedation vs propofol infusion for ERCP | |||||||||||||||||||||||||||||||||
| Medical condition: ERCP (Endoscopic Retrograde Cholangiopancreatography) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-002389-41 | Sponsor Protocol Number: ADJUBIL | Start Date*: 2022-02-25 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: biliary tract cancer | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2004-000327-15 | Sponsor Protocol Number: XL119-001 | Start Date*: 2004-11-25 | |||||||||||
| Sponsor Name:Exelixis, Inc. | |||||||||||||
| Full Title: A Phase 3 Multicenter, Single-Blind, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Bilary Tumors Not Amenable to Coventional Surgery | |||||||||||||
| Medical condition: Advanced Bilary Tract Tumours: Gall bladder cancer and Cholangiocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-014886-21 | Sponsor Protocol Number: BA_BICG_UMCG_1 | Start Date*: 2010-01-26 |
| Sponsor Name:University Medical Centre Groningen | ||
| Full Title: Intraoperative bile duct visualisation in children with biliary atresia using a fluorescence camera system: a pilot study | ||
| Medical condition: Biliary atresia | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-001014-32 | Sponsor Protocol Number: 2006-001014-32 | Start Date*: 2006-07-28 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
| Full Title: PHASE II STUDY OF BAY 43-9006 IN PATIENTS WITH ADVANCED CHOLANGIOCELLULAR CARCINOMA | |||||||||||||
| Medical condition: ᄋ Patients should have proven primary CCC according to one of the following criteria: o Histological evidence of CCC on a biopsy specimen. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-004580-21 | Sponsor Protocol Number: | Start Date*: 2007-09-14 |
| Sponsor Name:Erasme Hostpital - ULB | ||
| Full Title: 3T versus 1.5 T MR cholangiography using Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic acid (Primovist) | ||
| Medical condition: patients with known or suspected biliary disease will be enrolled and image quality of the MR cholangiography images will be assessed after Primovist administration. Biliary disease can include: bi... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-001173-96 | Sponsor Protocol Number: PHOTOSTENT-02 | Start Date*: 2005-10-26 |
| Sponsor Name:University College London | ||
| Full Title: Porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours: a multicentre, randomised, phas... | ||
| Medical condition: Advanced or metastatic cholangiocarcinomas and other biliary tract tumours | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-004444-38 | Sponsor Protocol Number: GAIN/GEM/CIS | Start Date*: 2019-01-11 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Krankenhaus Nordwest gGmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally det... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: incidental gallbladder carcinoma (IGBC) or biliary tract cancer (BTC) (intrahepatic cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC)) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2005-003318-13 | Sponsor Protocol Number: HE3002 | Start Date*: 2005-10-04 |
| Sponsor Name:The University of Southampton | ||
| Full Title: A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer. | ||
| Medical condition: Partients who have undergone surgical resection of a biliary tract cancer (including intrahepatic and extrahepatic cholangiocarcinoma, cancer of the distal bile duct and muscle invasive gallbladder... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-004981-14 | Sponsor Protocol Number: OOI/KEMB/2006-2 | Start Date*: 2006-12-20 |
| Sponsor Name:National Institute of Oncology, Budapest, Hungary | ||
| Full Title: Phase II., non randomized, open study: inoperable gall bladder or biliary tract EGFR expressing carcinoma treatment with Erbitux and 5-fluorouracil, epiadriamycin, mitomycin containing combination ... | ||
| Medical condition: Irresectable biliary tract cancer where palliation is the aim. It could be locally extanded and also metastatic cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-001500-18 | Sponsor Protocol Number: 1403-0011 | Start Date*: 2022-11-07 | ||||||||||||||||
| Sponsor Name:Boehringer Ingelheim España S.A. | ||||||||||||||||||
| Full Title: Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract ade... | ||||||||||||||||||
| Medical condition: cancer in the biliary tract or pancreas | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) BE (Trial now transitioned) NO (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2008-004560-39 | Sponsor Protocol Number: ACCORD 18/0803 | Start Date*: 2009-05-11 | |||||||||||
| Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) | |||||||||||||
| Full Title: Essai de phase III multicentrique randomisé, comparant l’effet d’une chimiothérapie adjuvante de 6 mois par gemcitabine-oxaliplatine à 85mg/m² (GEMOX 85) à une surveillance, chez des patients opér... | |||||||||||||
| Medical condition: Cancers des voies biliaires intra et extra hépatiques et des cancers de la vésicule réséqués. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004385-34 | Sponsor Protocol Number: ICM_2013/09 | Start Date*: 2014-05-27 | |||||||||||
| Sponsor Name:Institut régional du Cancer - Montpellier - Val d'Aurelle | |||||||||||||
| Full Title: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial | |||||||||||||
| Medical condition: advanced Biliary Tract Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-007152-94 | Sponsor Protocol Number: 02-2008 | Start Date*: 2009-01-30 | |||||||||||
| Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY | |||||||||||||
| Full Title: Efficacy and Safety of RAD001 (Everolimus) in Patients Affected by Biliary Tract Cancer Progressing After Prior Chemotherapy: a Phase II I.T.M.O. Study | |||||||||||||
| Medical condition: Patients affected by biliary tract cancer progressing after prior chemotherapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.